By Fineline Cube 
The U.S. Food and Drug Administration (FDA) granted approval to Merus N.V.’s Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma, marking the first approved therapy for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring this specific genetic alteration. The bispecific antibody becomes the seventh drug approved under the FDA’s Center for Novel and Pioneering Ventures (CNPV) pilot program.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Merus N.V. |
| Product | Bizengri (zenocutuzumab-zbco) – bispecific antibody |
| New Indication | NRG1 fusion-positive cholangiocarcinoma |
| Regulatory Status | Full FDA approval (week of May 12, 2026) |
| Previous Approval | Accelerated approval in December 2024 for NRG1+ NSCLC and pancreatic adenocarcinoma |
| CNPV Program | Seventh drug approved under FDA’s Center for Novel and Pioneering Ventures pilot |
Product Profile & Mechanism
- Molecule Type: Bispecific antibody targeting HER2 and HER3
- Mechanism of Action:
- Simultaneously blocks HER2-HER3 binding
- Prevents NRG1 fusion proteins from interacting with HER3
- Interrupts aberrant signaling pathway at its source
- Inhibits tumor growth driven by NRG1 fusions
- Target Population: Patients with rare NRG1 gene fusions across multiple tumor types
- Therapeutic Innovation: First-in-class approach specifically designed for NRG1 fusion-driven cancers
- Development Strategy: Tumor-agnostic approval strategy based on molecular biomarker rather than tissue of origin
Strategic Significance
| Aspect | Details |
|---|---|
| Cholangiocarcinoma Unmet Need | Limited effective therapies for advanced disease; median survival typically <12 months |
| Precision Medicine Advancement | Validates tumor-agnostic regulatory pathway for rare molecular subsets |
| CNPV Program Success | Demonstrates effectiveness of FDA’s innovative approval pathway for breakthrough therapies |
| Market Leadership | Establishes Merus as pioneer in NRG1 fusion-targeted therapeutics |
The approval represents a significant advance in precision oncology, providing the first targeted therapy option for patients with NRG1 fusion-positive cholangiocarcinoma, a molecularly-defined subset of this aggressive biliary tract cancer.
Market Impact & Outlook
- NRG1 Fusion Prevalence | Cholangiocarcinoma: ~5–10% of cases; represents ~1,000–2,000 annual U.S. patients
- Competitive Landscape | No direct competitors for NRG1 fusion indication; potential for premium pricing as first-in-class
- Diagnostic Ecosystem | Drives adoption of comprehensive genomic profiling in cholangiocarcinoma
- Revenue Potential | Peak sales projection of $300–500 million annually across all NRG1+ indications
- Strategic Implications | Success validates Merus’ bispecific platform and tumor-agnostic development strategy
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for Bizengri. Actual results may differ due to risks including market adoption rates, competitive dynamics, diagnostic testing rates, and reimbursement decisions.-Fineline Info & Tech